Corticotropin releasing factor 2 receptor agonists
View Patent ↗Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
1. A non-native peptide having an amino acid sequence according to the formula:
NDDPPISIDLPX 12 X 13 LLRNMIEMARIENEREQAGLNAKYLAEV (SEQ ID NO: 531) wherein
X 12 is selected from the group consisting of F, L, Q, T, and Y; and
wherein if X 12 is F, then X 13 is selected from the group consisting of F, Y, H, L, and Q;
if X 12 is L, then X 13 is selected from the group consisting of F, I, Y, H, L, and Q; and
if X 12 is Q, T, or Y, then X 13 is Y.
2. A peptide according to claim 1 , wherein X 12 is F.
3. A peptide according to claim 1 , wherein X 12 is L.
4. A peptide according to claim 1 , wherein X 12 is Q.
5. A peptide according to claim 1 , wherein X 12 is T.
6. A peptide according to claim 1 , wherein X 12 is Y.
7. A peptide according to claim 1 , wherein X 13 is F.
8. A peptide according to claim 1 , wherein X 13 is I.
9. A peptide according to claim 1 , wherein X 13 is Y.
10. A peptide according to claim 1 , wherein X 13 is H.
11. A peptide according to claim 1 , wherein X 13 is L.
12. A peptide according to claim 1 , wherein X 13 is Q.
13. A peptide according to claim 1 , selected from the group consisting of SEQ ID Nos: 257-262, and 264.
14. A peptide according to claim 1 ,selected from the group consisting of SEQ ID Nos: 265-271.
15. A pharmaceutical composition comprising: (a) a safe and effective amount of a peptide according to claim 13 ; and (b) a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising: (a) a safe and effective amount of a peptide according to claim 14 ; and (b) a pharmaceutically acceptable carrier.
17. A kit for use in preventing or treating a CRF 2 R modulated disorder comprising: (a) a peptide according to claim 1 , in a unit dose form; and (b) usage instructions.
18. A method of preventing or treating a CRF 2 R modulated disorder comprising administering to a host in need of such treatment a safe and effective amount of a peptide according to claim 13 .
19. A method of preventing or treating a CRF 2 R modulated disorder comprising administering to a host in need of such treatment a safe and effective amount of a peptide according to claim 14 .
20. A method according to claim 18 , wherein the CRF 2 R modulated disorder is skeletal muscle atrophy or muscular dystrophy.
21. A method according to claim 19 , wherein the CRF 2 R modulated disorder is skeletal muscle atrophy or muscular dystrophy.